ly3410738
Small moleculeexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 16, 2020 (NCT04521686)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
IDH1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05205447 | Phase 1 | Jan 5, 2022 | Antengene Corporation, Eli Lilly, Loxo Oncology |
| NCT06181084 | Phase 1 | Oct 11, 2021 | Eli Lilly, Loxo Oncology |
| NCT06181045 | Phase 1 | Feb 24, 2021 | Eli Lilly, Loxo Oncology |
| NCT04603001 | Phase 1 | Nov 30, 2020 | Eli Lilly, Loxo Oncology |
| NCT04521686 | Phase 1 | Oct 16, 2020 | Antengene Corporation, Eli Lilly, Loxo Oncology |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 5 | 3 | 1 | 2020 |
| Loxo Oncology | For profit | 5 | 2 | 1 | 2020 |
| Antengene Corporation | For profit | 2 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1